Close Menu

NEW YORK – NeuMoDx has filed a response with the District of Delaware courts defending itself against claims levied by Becton Dickinson that the molecular diagnostics developer infringed on certain patents.

In court documents filed in Delaware on Friday, the Ann Arbor-based maker of high-throughput and mid-throughput PCR-based molecular diagnostic instruments and assays denied that it infringes any claim of the asserted patents and said that the asserted patents are invalid.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jun
04
Sponsored by
Ovation

This webinar will discuss the current status of COVID-19 testing, treatment and other aspects of the current pandemic as they relate to getting this outbreak under control.  

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.